FreeTheAI

Natera's Signatera Test Recognized on TIME Best Inventions List

BullishLow impact
NTRA$402.83 2.05%

Natera, Inc. (NTRA) announced that its Signatera molecular residual disease test was selected for TIME's Best Inventions of 2026 list in the Medical & Healthcare category. The blood-based diagnostic analyzes circulating tumor DNA to detect cancer recurrence up to two years earlier than standard imaging. The recognition underscores the expanding role of personalized diagnostics in modern oncology.

Signatera is currently used by more than 55% of oncologists in the United States and is backed by over 200 peer-reviewed scientific publications. By building a profile from the unique genomic signature of a patient's tumor, the test helps physicians guide treatment decisions and assists pharmaceutical companies in identifying candidates for clinical trials. Shares of Natera, Inc. traded up 1.45% to $400.50 following the update.

Moving forward, investors will keep an eye on Natera's commercial expansion and test adoption across clinical settings. The company was also recently named to Fortune's Future 120 list in October 2026, reflecting its growing presence across oncology, women's health, and organ health diagnostics.

Key points

  • Natera, Inc. (NTRA) had its Signatera cancer test selected for TIME's Best Inventions of 2026 list.
  • Signatera can detect cancer recurrence in blood up to two years prior to standard imaging.
  • The diagnostic test is currently utilized by more than 55% of oncologists across the United States.
  • Natera stock rose 1.45% to $400.50 on the day of the announcement.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What recognition did Natera, Inc. receive for its Signatera test?

Natera's Signatera test was named to TIME's Best Inventions of 2026 list in the Medical & Healthcare category.

How does Natera's Signatera test work?

Signatera analyzes circulating tumor DNA in blood based on a patient's unique tumor genome, detecting cancer recurrence up to two years before imaging.

How widely used is Natera's Signatera test in the U.S.?

Signatera is used by over 55% of oncologists in the United States and is supported by more than 200 peer-reviewed publications.